Variant ID: 9-27228564-G-A


This variant was identified in 1 publication


Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

Plos One
I Makhoul, VK Todorova, ER Siegel, SW Erickson, I Dhakal, VR Raj, JY Lee, MS Orloff, RJ Griffin, RS Henry-Tillman, S Klimberg, LF Hutchins, SA Kadlubar
Publication Date: 2017

Variant appearance in text: rs10812540
PubMed Link: 28045923
PubMed Central Link
Variant Present in the following documents:
  • pone.0168550.s011.xlsx
  • pone.0168550.s006.xlsx
  • pone.0168550.s007.xlsx
  • pone.0168550.s004.xlsx
  • pone.0168550.s009.xlsx
  • pone.0168550.s005.xlsx
  • pone.0168550.s003.xlsx
View BVdb publication page

Alternative transcript annotations:

Transcript cDNA Protein Consequence Exon Intron
ENST00000380036.4 c.3300+261G>A - intron_variant - 22/22
ENST00000406359.4 c.3171+261G>A - intron_variant - 21/21
ENST00000519097.1 c.2856+261G>A - intron_variant - 20/20
NM_000459.4 c.3300+261G>A - intron_variant - 22/22
NM_001290077.1 c.3171+261G>A - intron_variant - 21/21
NM_001290078.1 c.2856+261G>A - intron_variant - 20/20